Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
NCT00477087Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Jul 2006
- Primary completion
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in prostate cancer (PCa), sponsored by Stanford University. Primary endpoint: Progression-free Survival at 18 months. Started Jul 2006; status: terminated.
02
Drugs
sargramostim
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00477087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477087.